OBJECTIVE: The purpose of this study is to investigate the effectiveness of introducing clinical pharmacy services in achieving goal lipid profile in dyslipidemia patients in North of Jordan. Setting the study was carried out in a primary care facility in North of Jordan. METHODS:One hundred fifty two dyslipidemia patients were randomized into intervention and control groups and followed for 6 months period. Intervention group patients were followed intensively by a clinical pharmacist who worked closely with physicians in controlling lipid profiles according to the third edition of recommendations by The National Cholesterol Education Program Adult Treatment Panel, control group patients were provided with standard medical care. Main outcome measure percent of patients at their low density lipoprotein cholesterol target in the intervention group compared to percent of patients at their low density lipoprotein cholesterol target in the control group by the end of the study. RESULTS:One hundred twenty five patients completed the study duration. After 6 months, 94.5% of intervention group patients and 71.2 % of control group patients reached their goal low density lipoprotein cholesterol levels (P value < 0.001, Pearson Chi-Square test) compared to 24.7 and 28.8% respectively at baseline. Majority of pharmacist recommendations (90.4%) were followed by physicians and overall lipid lowering agents use was increased to 91.8% in intervention group patients and 86.5% in control group patients compared to 69.9 and 78.8% respectively at baseline. CONCLUSION: Implementing clinical pharmacy services in Jordan has improved the lipid profiles of dyslipidemic patients.
RCT Entities:
OBJECTIVE: The purpose of this study is to investigate the effectiveness of introducing clinical pharmacy services in achieving goal lipid profile in dyslipidemiapatients in North of Jordan. Setting the study was carried out in a primary care facility in North of Jordan. METHODS: One hundred fifty two dyslipidemiapatients were randomized into intervention and control groups and followed for 6 months period. Intervention group patients were followed intensively by a clinical pharmacist who worked closely with physicians in controlling lipid profiles according to the third edition of recommendations by The National Cholesterol Education Program Adult Treatment Panel, control group patients were provided with standard medical care. Main outcome measure percent of patients at their low density lipoprotein cholesterol target in the intervention group compared to percent of patients at their low density lipoprotein cholesterol target in the control group by the end of the study. RESULTS: One hundred twenty five patients completed the study duration. After 6 months, 94.5% of intervention group patients and 71.2 % of control group patients reached their goal low density lipoprotein cholesterol levels (P value < 0.001, Pearson Chi-Square test) compared to 24.7 and 28.8% respectively at baseline. Majority of pharmacist recommendations (90.4%) were followed by physicians and overall lipid lowering agents use was increased to 91.8% in intervention group patients and 86.5% in control group patients compared to 69.9 and 78.8% respectively at baseline. CONCLUSION: Implementing clinical pharmacy services in Jordan has improved the lipid profiles of dyslipidemic patients.
Authors: Michael H Davidson; Leiv Ose; Jiri Frohlich; Russell S Scott; Carlos A Dujovne; Ivan D Escobar; Marcelo C Bertolami; Frank Cihon; Darbie L Maccubbin; Michele Mercuri Journal: Clin Cardiol Date: 2003-11 Impact factor: 2.882
Authors: Mohammad Fathullah Zaitoun; Mais Hasan Iflaifel; Loloah Abdullah Almulhim; Mohammed Ali Al-Ghamdi; Yasir Ahmed Ibrahim Journal: J Pharm Bioallied Sci Date: 2019 Apr-Jun
Authors: Francisco Martínez-Mardones; Fernando Fernandez-Llimos; Shalom I Benrimoj; Antonio Ahumada-Canale; José Cristian Plaza-Plaza; Fernanda S Tonin; Victoria Garcia-Cardenas Journal: J Am Heart Assoc Date: 2019-11-12 Impact factor: 5.501